What is your current approach to maintenance therapy in FLT3-mutant AML post allogeneic HCT?
1
1 Answers
Mednet Member
Medical Oncology · University of Maryland Cancer Center
I would offer maintenance with FLT3 inhibitor with gilteritinib (NCT02997202: MORPHO trial, not yet published), sorafenib (SORMAIN trial), or midostaurin (RADIUS trial), whichever agent is available. In my experience, gilteritinib appears to be the most tolerable. I suggest beginning maintenance as ...